Interestingly, it was recently shown that the prognostic impact of FLT3‐ITD mutations is also age‐dependent, with poor overall survival observed in younger FLT3‐ITD‐mutated (< 60 years) AML patients, but not within the older population (60–74 years) [11]. This evidence concerns the gene FLT3 and acute myeloid leukemia.